Compare Tencent Music Entertainment Group - ADR (TME) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tencent Music Entertainment Group - ADR vs Vertex Pharmaceuticals Incorporated — how do they compare? Tencent Music Entertainment Group - ADR trades at $9.16 (market cap $15.08B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.1× Tencent Music Entertainment Group - ADR's market cap, and Tencent Music Entertainment Group - ADR pays a 2.62% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| TME | VRTX | |
|---|---|---|
Market Cap | $15.08B | $121.95B |
Sector | Media | Health |
52-Week High | $26.36 | $529.59 |
52-Week Low | $8.16 | $366.54 |
Enterprise Value | $11.85B | $116.69B |
Dividend Yield | 2.62% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
